Company intelligence / Profile preview

BioSTAR Group

Ownership: Private
Development stage: Commercial

Overview

Beijing Biostar’s lead product, Utidelone Injectable (UTD1), is a next-generation microtubule inhibitor approved by China’s NMPA in March 2021 for metastatic breast cancer. Phase III data showed significant improvements over standard regimens in progression-free survival and overall survival. The product has been included as a Class I recommendation in the 2024 CSCO Guidelines for Breast Cancer. The pipeline includes 19 programs spanning indication expansions of Utidelone and new formulations/platforms at various stages from preclinical to multinational clinical studies

Therapeutic areas: Oncology
Modalities: Small moleculesNano-formulations
Industry: Biotech

Drug pipeline

4 assets

BG22

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Baheal Intelligent Technology/Baheal Medical – exclusive promotion rights agreement for Utidelone Injection in mainland China with milestone payments and commercialization collaboration

Beyond the preview

Go deeper on BioSTAR Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioSTAR Group.

Explore the full profile